The FDA granted a Clinical Laboratory Improvement Amendments to TearLab to widen the use of its Osmolarity System, a test for dry eye, according to a Reuter's report.
The change came after the device was reclassified to "simple" instead of "moderately complex". Previously, an eye practice had to obtain CLIA certification through paperwork and a 20-hour CME course to use the device. Company shares were trading up at much as 80 percent after the announcement.
Related Articles on Ophthalmology:
Thyroid Eye Disease Sufferers Who Smoke More Likely to Need Surgery
Guidelines for Treatment Course of Age-Related Macular Degeneration Updated
BIOLASE Laser Technology Issued Patent to Treat Eye Conditions
The change came after the device was reclassified to "simple" instead of "moderately complex". Previously, an eye practice had to obtain CLIA certification through paperwork and a 20-hour CME course to use the device. Company shares were trading up at much as 80 percent after the announcement.
Related Articles on Ophthalmology:
Thyroid Eye Disease Sufferers Who Smoke More Likely to Need Surgery
Guidelines for Treatment Course of Age-Related Macular Degeneration Updated
BIOLASE Laser Technology Issued Patent to Treat Eye Conditions